Publications Archives - Double Bond Pharmaceutical

Local chemotherapy in treatment of brain tumors. Part 2. Efficiency of treatment of patients with neuroepithelial brain tumors secondary to intraoperative local chemotherapy

By gustav|2025-02-19T00:34:43+01:00February 19th, 2025|

According to the results of open, controlled, retro prospective, comparative, randomized clinical trial found an increase in the efficacy of the combined treatment of malignant brain tumors in the application of intraoperative local chemotherapy drug (LHT) temodex. In particular, the median survival of patients with Grade III–IV tumors in the supratentorial localization background [...]

Local chemotherapy in treatment of brain tumors. Part 1. Characteristics of neurosurgical intervention and the course of the postoperative period in patients with brain tumors secondary to local chemotherapy

By gustav|2025-02-19T00:20:22+01:00February 19th, 2025|

The assessment of the clinical progression of the postoperative period in patients with neuroepithelial brain tumors when using intraoperative local chemotherapy (iLCT) with Temodex, which is an anticancer medicinal product of the active substance of temozolomide immobilized on highly substituted dextran phosphate. Clinical manifestations and features of the early postoperative period were analyzed depending [...]

Local delivery of temozolomide via a biologically inert carrier (Temodex)

By gustav|2025-02-05T22:54:38+01:00February 5th, 2025|

Glioma is the most common brain malignancy. Standard first-line therapy for glioma includes surgery, radiotherapy and systemic administration of temozolomide. However, temozolomide does not reach the brain in sufficient doses when administered orally and has poor efficiency in more than half of the patients. Strategies to improve the treatment of glial malignancies are [...]

Cancer neuroscience and glioma (2025)

By gustav|2025-02-04T13:58:50+01:00January 27th, 2025|

In recent years, it has been increasingly recognized that tumor growth relies not only on support from the surrounding microenvironment but also on the tumors capacity to adapt to - and actively manipulate - its niche. While targeting angiogenesis and modulating the local immune environment have been explored as therapeutic approaches, these strategies [...]

Temodex prolongs survival in glioma patients 2019

By gustav|2024-06-18T20:04:40+02:00June 18th, 2024|

Temodex prolongs survival in glioma patients 2019 Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow [...]

Our expert view on Drug Delivery 2017

By gustav|2018-11-20T23:44:01+01:00November 19th, 2018|

Our expert view on Drug Delivery 2017 Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow [...]